First CAR T-cell therapy recommended for routine use on the NHS in England

26 January 2023

The UK’s health technology assessor has approved the first chimeric antigen receptor (CAR) T-cell therapy for use on the National Health Service (NHS) in England.

Revealing the news, US biotech major Gilead Sciences (Nasdaq: GILD) and its Kite subsidiary today said that the National Institute for Health and Care Excellence (NICE) has recommended their Yescarta (axicabtagene ciloleucel; axi-cel) for routine commissioning by NHS England for the treatment of some adults with certain forms of lymphoma.

Specifically, patients with diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) who have already been treated with two or more systemic therapies may be eligible for treatment. Through the Cancer Drugs Fund, in 2018, England was the first country in Europe to provide access to a chimeric antigen receptor (CAR) T-cell therapy to treat these blood cancers, and since then over 500 patients in England have received axi-cel. Yescarta generated global sales of $317 million in the third quarter of last year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK